Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry-Reference-Cited by-同舟云学术

Dyspnea in patients treated with P2Y12 receptor antagonists: insights from the GReek AntiPlatElet (GRAPE) registry

Published:2017-02-02 Issue:7 Volume:28 Page:691-697
ISSN:0953-7104
Container-title:Platelets
language:en
Short-container-title:Platelets

Author:

Alexopoulos Dimitrios¹²,Xanthopoulou Ioanna¹,Perperis Angelos¹,Goudevenos John³,Hamilos Michalis⁴,Sitafidis George⁵,Kanakakis Ioannis⁶,Vavouranakis Manolis⁷,Giannopoulos George²⁸,Barampoutis Nikolaos¹,Deftereos Spyridon²⁸,Lekakis John²

Affiliation:

1. Department of Cardiology, Patras University Hospital, Patras, Greece

2. Department of Cardiology, Attikon University Hospital, Athens, Greece, Athens, Greece

3. Department of Cardiology, Ioannina University Hospital, Ioannina, Greece

4. Department of Cardiology, Iraklion University Hospital, Iraklion, Greece

5. Department of Cardiology, Larissa University Hospital, Larissa, Greece

6. Department of Clinical Therapeutics, “Alexandra” University Hospital, Athens, Greece

7. 1st University Department of Cardiology, Ippokration Hospital, Athens, Greece

8. Department of Cardiology, Athens General Hospital “G. Gennimatas”, Athens, Greece

Funder

Hellenic Cardiological Society

Publisher

Informa UK Limited

Subject

Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/09537104.2016.1265919

Reference27 articles.

1. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

2. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

3. Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

4. Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study

5. Ticagrelor Enhances Adenosine-Induced Coronary Vasodilatory Responses in Humans

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention;JACC: Cardiovascular Interventions;2023-10

2. Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction - A Time Dependent Analysis Study;ACTA CARDIOL SIN;2020

3. De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives;Journal of Cardiovascular Pharmacology and Therapeutics;2019-02-05

4. Oral antiplatelets in primary and secondary prevention of myocardial infarction: a review;Irish Journal of Medical Science (1971 -);2018-09-03

5. Caffeine and incidence of dyspnea in patients treated with ticagrelor;American Heart Journal;2018-06